Ginkgo Bioworks Holdings, Inc.
DNA
$6.79
-$0.45-6.22%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -48.49% | -49.06% | -23.84% | -56.39% | -30.37% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -48.49% | -49.06% | -23.84% | -56.39% | -30.37% |
| Cost of Revenue | -68.05% | -24.25% | -24.12% | 6.66% | -60.79% |
| Gross Profit | -45.38% | -52.03% | -23.75% | -66.21% | -20.55% |
| SG&A Expenses | -23.13% | -9.81% | -11.49% | -14.03% | -41.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.29% | -22.32% | -25.03% | -10.04% | -54.56% |
| Operating Income | 1.33% | 9.34% | 25.59% | -68.93% | 63.16% |
| Income Before Tax | -6.95% | 8.51% | 24.54% | -42.23% | 75.36% |
| Income Tax Expenses | 145.23% | -190.91% | -97.85% | 100.27% | -248.95% |
| Earnings from Continuing Operations | -7.76% | 8.70% | 24.91% | -43.18% | 75.51% |
| Earnings from Discontinued Operations | 249.32% | 14.63% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.54% | 9.20% | 24.91% | -43.18% | 72.24% |
| EBIT | 1.33% | 9.34% | 25.59% | -68.93% | 63.16% |
| EBITDA | -5.58% | 7.82% | 26.57% | -82.09% | 71.76% |
| EPS Basic | 31.57% | 17.32% | 29.20% | -34.44% | 74.00% |
| Normalized Basic EPS | 3.74% | 13.78% | 31.90% | -94.60% | 65.64% |
| EPS Diluted | 31.57% | 17.32% | 28.97% | -34.39% | 74.02% |
| Normalized Diluted EPS | 3.74% | 13.78% | 31.90% | -94.60% | 65.63% |
| Average Basic Shares Outstanding | 13.19% | 9.81% | 6.07% | 6.50% | 6.79% |
| Average Diluted Shares Outstanding | 13.19% | 9.81% | 6.07% | 6.48% | 6.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |